Fate Therapeutics Inc
Fate Therapeutics Inc (FATE) Historical Volatility
FATE's 30 day historical volatility is 94.69%, in the 73rd percentile of readings over the past year. This is a high percentile, meaning Fate Therapeutics Inc shares have swung far more than usual. FATE's 30 day implied volatility sits at 456.73%, with an IV Rank of 98.81%, leaving IV 362.04 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.
Read more
Tracking FATE historical volatility helps you see how much Fate Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, FATE's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor FATE 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. FATE's 30 day historical volatility, or FATE HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing FATE's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 13, 2026
As of Nov 13, 2026
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →